Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions - PubMed (original) (raw)

Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions

T Dorfman et al. J Virol. 1997 Sep.

Abstract

Human immunodeficiency virus type 1 (HIV-1) incorporates the cellular peptidyl-prolyl cis-trans isomerase cyclophilin A (CyPA), the cytosolic receptor for the immunosuppressant cyclosporin A (CsA). CsA inhibits the incorporation of CyPA and reduces HIV-1 virion infectivity but is inactive against closely related primate lentiviruses that do not interact with CyPA. The incorporation of CyPA into HIV-1 virions is mediated by a specific interaction with a proline-containing, solvent-exposed loop in the capsid (CA) domain of the Gag polyprotein. CsA, which disrupts the interaction with CA, binds at the active site of CyPA. To test whether active-site residues are also involved in the interaction with HIV-1 CA, we used a panel of previously characterized active-site mutants of human CyPA. Expression vectors for epitope-tagged wild-type and mutant CyPA were transfected into COS-gamma cells along with HIV-1 proviral DNA, and the virions produced were analyzed for the presence of tagged proteins. Cotransfection of the wild-type expression vector led to the incorporation of readily detectable amounts of epitope-tagged CyPA into HIV-1 virions. One CyPA mutant with a substantially decreased sensitivity to CsA was incorporated with wild-type efficiency, demonstrating that the requirements for binding to CsA and to HIV-1 CA are not identical. The remaining six CyPA mutants were incorporated with markedly reduced efficiency, providing in vivo evidence that HIV-1 CA interacts with the active site of CyPA.

PubMed Disclaimer

Similar articles

• Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence.
  Bukovsky AA, Weimann A, Accola MA, Göttlinger HG. Bukovsky AA, et al. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10943-8. doi: 10.1073/pnas.94.20.10943. Proc Natl Acad Sci U S A. 1997. PMID: 9380739 Free PMC article.
• The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein.
  Braaten D, Ansari H, Luban J. Braaten D, et al. J Virol. 1997 Mar;71(3):2107-13. doi: 10.1128/JVI.71.3.2107-2113.1997. J Virol. 1997. PMID: 9032343 Free PMC article.
• Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization.
  Colgan J, Yuan HE, Franke EK, Luban J. Colgan J, et al. J Virol. 1996 Jul;70(7):4299-310. doi: 10.1128/JVI.70.7.4299-4310.1996. J Virol. 1996. PMID: 8676452 Free PMC article.
• Cyclophilin, TRIM5, and innate immunity to HIV-1.
  Sokolskaja E, Luban J. Sokolskaja E, et al. Curr Opin Microbiol. 2006 Aug;9(4):404-8. doi: 10.1016/j.mib.2006.06.011. Epub 2006 Jul 3. Curr Opin Microbiol. 2006. PMID: 16815734 Review.
• Insights into the roles of cyclophilin A during influenza virus infection.
  Liu X, Zhao Z, Liu W. Liu X, et al. Viruses. 2013 Jan 15;5(1):182-91. doi: 10.3390/v5010182. Viruses. 2013. PMID: 23322171 Free PMC article. Review.

Cited by

• Rescue of HIV-1 release by targeting widely divergent NEDD4-type ubiquitin ligases and isolated catalytic HECT domains to Gag.
  Weiss ER, Popova E, Yamanaka H, Kim HC, Huibregtse JM, Göttlinger H. Weiss ER, et al. PLoS Pathog. 2010 Sep 16;6(9):e1001107. doi: 10.1371/journal.ppat.1001107. PLoS Pathog. 2010. PMID: 20862313 Free PMC article.
• Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.
  Chen S, Zhao X, Tan J, Lu H, Qi Z, Huang Q, Zeng X, Zhang M, Jiang S, Jiang H, Yu L. Chen S, et al. Eur J Pharmacol. 2007 Jun 22;565(1-3):54-9. doi: 10.1016/j.ejphar.2007.03.023. Epub 2007 Mar 24. Eur J Pharmacol. 2007. PMID: 17449029 Free PMC article.
• The role of immunophilins in viral infection.
  Hopkins S, Gallay PA. Hopkins S, et al. Biochim Biophys Acta. 2015 Oct;1850(10):2103-10. doi: 10.1016/j.bbagen.2014.11.011. Epub 2014 Nov 18. Biochim Biophys Acta. 2015. PMID: 25445708 Free PMC article.
• Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr.
  Ardon O, Zimmerman ES, Andersen JL, DeHart JL, Blackett J, Planelles V. Ardon O, et al. J Virol. 2006 Apr;80(8):3694-700. doi: 10.1128/JVI.80.8.3694-3700.2006. J Virol. 2006. PMID: 16571786 Free PMC article.
• Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.
  Sokolskaja E, Sayah DM, Luban J. Sokolskaja E, et al. J Virol. 2004 Dec;78(23):12800-8. doi: 10.1128/JVI.78.23.12800-12808.2004. J Virol. 2004. PMID: 15542632 Free PMC article.

References

1. 1. Science. 1984 Nov 2;226(4674):544-7 - PubMed
2. 1. Mol Cell Biol. 1988 Jan;8(1):466-72 - PubMed
3. 1. Nature. 1989 Feb 2;337(6206):473-5 - PubMed
4. 1. Nature. 1989 Feb 2;337(6206):476-8 - PubMed
5. 1. Science. 1991 Jan 18;251(4991):283-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database